1263 results about "Glycoprotein" patented technology

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and / or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

The invention provides a decellularized amnion matrix hydrogel and a preparation method thereof. The preparation method comprises the following steps: amnion tissue pretreatment, cleaning, decellularization, grinding, freeze-drying, digestion and acid-base neutralization. According to the decellularized amnion matrix hydrogel, active cells are removed while collagen, fibronectin, glycoprotein and other components in an amnion cell matrix are reserved, and the immunogenicity of the decellularized amnion matrix hydrogel is reduced from the source. The decellularized amniotic membrane matrix hydrogel provided by the invention can simulate the microenvironment of in-vivo cells, provides support and signals required by cell adhesion and growth, can be used for constructing a tissue engineering scaffold, and provides support for directional growth and tissue regeneration of cells. Besides, the decellularized amniotic membrane matrix hydrogel can also be used as a drug carrier for in-vivo drug release and treatment, and has very high application potential in medical research and clinical application.

Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and / or treating an Ebola virus infection in a subject using said composition and method of generation.

The present invention the invention concerns bifunctional compounds of Formula (I) A-T-L1-AG, Formula (II) A-L1-Con(L2-AG)n or Formula (III) Ak´-Th-L3 ii-AGj' wherein A is a protein that binds to the hinge region of galactose deficient IgA1 antibodies or a protein that binds to autoantibodies of galactose deficient IgA antibodies and AG is an asiaglycoprotein receptor binding moiety (ASGPR binding moiety). L1, Con and L2 are part of a linker between A and AG. The A has the ability to bind to antibodies that are a cause of IgA nephropathy and the asiaglycoprotein receptor binding moiety binds to hepatic cells thereby initiating endocytosis and removal of the antibodies that are a cause of IgA nephropathy from the blood stream.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

The invention discloses a tetravalent platinum autophagy inducer with a structure of a general formula I as well as a preparation method and application of the tetravalent platinum autophagy inducer. The compound disclosed by the invention has an induction effect on cell autophagy, and can be used for degrading immunosuppressive protein tenascin-C (Tenascinin-C) through autophagy so as to improve a tumor immunosuppressive microenvironment. The tetravalent platinum complex induces tumor cells to generate autophagic death through unique structural characteristics, promotes immune killer cells to infiltrate a tumor immune microenvironment, can be used for preparing novel chemical immunotherapy drugs with multiple anti-tumor mechanisms, and has broad application prospects. The problems that the traditional treatment effect is poor and a small molecule immunotherapeutic agent is lacked are solved. # imgabs0 #

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The invention discloses an antibody and a kit for targeting human desmogranuloprotein 2. The antibody comprises a light chain variable region and a heavy chain variable region, the heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody has high affinity with deodontoprotein-2, and a kit developed by using the antibody can realize high-sensitivity quantitative detection of DSC2, thereby not only being beneficial to basic research, but also being capable of providing valuable reference information for clinical diagnosis.

The invention provides an anti-beta2-glycoprotein I antibody detection reagent and a chemiluminescence detection kit, and the anti-beta2-glycoprotein I antibody detection reagent comprises a biotin-labeled beta2-glycoprotein I antigen prepared by reacting biotin connected with an LPETG label with the beta2-glycoprotein I antigen under the catalytic action of Sortase A enzyme. The N terminal of the beta2-glycoprotein I antigen is labeled with the biotin with a specific label in a fixed point manner, all amino acid sequence regions (structural domains I-V) of the beta2-glycoprotein I antigen are not influenced, and meanwhile, the purity of a connection product is high, the difference between batches is small, and the method is suitable for large-scale production. The positive detection rate and the detection result accuracy of the anti-beta2-glycoprotein I antibody magnetic particle chemiluminescence detection kit can be improved, and the difference between batches can be reduced.

The invention relates to the technical field of stem cells, in particular to a lentivirus envelope plasmid combination and application thereof, a lentivirus and a packaging method thereof and a method for transduction of hematopoietic stem cells. The invention provides an envelope plasmid combination for lentivirus packaging, which is composed of lentivirus packaging plasmids containing VSVG glycoprotein and lentivirus packaging plasmids containing BaEV glycoprotein in a ratio of 3: 7. The invention further provides a method for transduction of the hematopoietic stem cells by the lentivirus, the method is simple and convenient to operate, the long-term dryness of the hematopoietic stem cells in vitro can be maintained, efficient and stable transduction of the hematopoietic stem cells can be realized, and the transduction rate is greater than 90%. The lentivirus transduction method hematopoietic stem cells can be used for hematopoietic stem cell gene therapy hematopoietic system genetic diseases, such as severe combined immunodeficiency, beta-thalassemia and sickle cell disease, Wiskott-Aldrich syndrome and the like, and the application prospect is good.

The present disclosure provides amino acid sequences (e.g., antibodies) capable of binding to glypican 3 protein (GPC3). The present disclosure relates to antigen binding fragments of GPC3 antibodies; conjugates of a GPC3 antibody, including an immunoconjugate; bispecific antibodies comprising a GPC3 antibody and related compositions and formulations. The disclosure also relates to methods of treating GPC3-related diseases, disorders and conditions, including cell proliferative diseases, such as cancer, more particularly liver cancer, using these sequences, such as GPC3 antibodies and antigen-binding fragments thereof.

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The invention belongs to the technical field of skin care, and discloses an anti-wrinkle composition, application, a skin care product and anti-wrinkle essence cream, and the anti-wrinkle composition is prepared from the following components in parts by weight: 1-2 parts of okra hydrolyzed glycoprotein, 10-20 parts of spanishneedles herb extract, 1-2 parts of XVII type collagen, 1-2 parts of III type micromolecular collagen and 6-12 parts of cordyceps sinensis extract. The invention discloses an anti-wrinkle composition. Okra hydrolyzed glycoprotein, a spanishneedles herb extract, XVII type collagen, III type micromolecular collagen and a cordyceps sinensis extract are compounded to generate the effect of synergistically improving the anti-wrinkle effect of the composition. Through compounding of the five components, lost collagen is directly supplemented for the skin, the collagen production capacity of the skin is stimulated, and lasting compactness and smoothness of the skin are achieved.

The application discloses a method for recovering active glycoprotein Patatin from potato starch processing waste juice, and belongs to the technical field of protein extraction. The method is characterized in that the active Patatin protein is efficiently separated by using the combination of ammonium sulfate fractionation precipitation, anion exchange chromatography, Con A affinity chromatography and gel chromatography, and the obtained Patatin protein retains the original protein structure and biological function activity. Compared with the prior art, the method has better separation purity and higher efficiency, and the obtained Patatin protein has complete protein higher structure and function activity, and has a better application scene.

Provided herein are non-naturally occurring variants of the hepatitis B virus (HBV) Core protein, the HBV polymerase N-terminal domain, and the HBV polymerase C-terminal domain, as well as immunogenic fragments thereof. Fusion proteins comprising the HBV variants fused to a herpes simplex virus (HSV) glycoprotein (gD) sequence, as well as methods of using the fusion proteins, are also provided.

The invention provides a Chinese herbal medicine composition for improving immunity as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: fermenting rhizoma anemarrhenae, poria cocos, rhizoma polygonati and fructus lycii to prepare Chinese herbal medicine selenium / germanium-rich polysaccharide, carrying out carboxylation modification on the Chinese herbal medicine selenium / germanium-rich polysaccharide and phycobiliprotein to prepare a Chinese herbal medicine selenium / germanium-rich polysaccharide-phycobiliprotein compound, and dissolving bacterial sludge in the fermentation process with helicase to prepare a bacteria-dissolving product; and uniformly stirring and mixing with the Chinese herbal medicine selenium / germanium-rich polysaccharide-phycobiliprotein compound, berberine and camptothecin to prepare the Chinese herbal medicine composition for improving immunity. The prepared Chinese herbal medicine composition capable of improving immunity contains rich glycoprotein and organic selenium / germanium compounds, has the effects of consolidating body resistance and strengthening yang, has the advantages of good sterilization, oxidation resistance, inflammation resistance, virus resistance and tumor resistance, no toxicity, high bioavailability, easiness in absorption and the like, is high in patient compliance and has a wide application prospect.

Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

The invention relates to the technical field of biomedical materials and tissue engineering, in particular to a bionic skin model for drug transdermal release research. The hydrogel has skin-like epidermis and dermis structures, the epidermis structure is composed of an electrostatic spinning high-molecular polymer, and the dermis structure is composed of an interpenetrating hydrogel skeleton formed by interweaving polysaccharide, protein and lipid. By adjusting the thickness and composition of the bionic skin, the bionic skin can show a transdermal drug release behavior similar to that of traditional in-vitro skin (such as pigskin, human skin and rat skin) in drug transdermal penetration research, so that the bionic skin is suitable for research on transdermal penetration and absorption behaviors of drugs in external preparations such as ointment, patches and skin care products; and an alternative scheme which is more consistent with ethics, stable, economic and good in reproducibility is provided for prescription screening, quality evaluation and the like.

Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.

The invention discloses a recombinant protein for detecting an anti-myelin sheath related glycoprotein MAG antibody and a detection reagent of the recombinant protein, and belongs to the technical field of neural immunodiagnostics, five amino acid sites in MAG protein are subjected to specific amino acid point mutation replacement to obtain an MAG protein mutation sequence, the MAG protein mutation sequence is fused with GlcATP enzyme and HNK-1ST enzyme full-length sequences to construct a lentiviral expression vector, and the recombinant protein and the detection reagent are used for detecting the anti-myelin sheath related glycoprotein MAG antibody. According to the present invention, three genes are constructed, and are stably transfected in a host cell so as to stably express the three genes in one cell at the same time, such that the constructed recombinant protein and the wild type MAG protein have similar anti-MAG IgM antibody binding domain, and on the premise of not using GlcATP enzyme and HNK-1ST enzyme small molecule agonists, the sensitivity and the specificity of the detection of the MAG autoimmune antibody by using the CBA method are improved; the method is suitable for preparing related detection reagents for in-vitro detection of the IgM type anti-MAG antibody.

The present disclosure provides a polyribonucleotide encoding a polypeptide that comprises a viral antigen from Herpes Simplex Virus-2 (HSV-2); for example, the viral antigen comprises the ectodomain of HSV-2 glycoprotein B. The polyribonucleotide can be formulated as an RNA composition useful for inducing anti-HSV immune responses in a subject.

In some aspects, provided herein are antibodies or antigen-binding fragments that bind to the glycoprotein receptor CD200R present on the surface of a cell. In some cases, the antibodies or antigen binding fragments provided herein agonize the CD200R signaling pathway that inhibits inflammatory and immune responses. In other aspects, provided herein are compositions, methods of use, methods of preparation, polynucleotides, vectors, host cells, and kits related to antibodies or antigen-binding fragments that bind to CD200R.

Systems and methods for the automatic quantification of sialic acid of polypeptides in near real time.

In aspects, the present disclosure provides a recombinant protein comprising (a) a rhabdoviral G glycoprotein or a functional fragment or derivative thereof, wherein the rhabdoviral G glycoprotein or functional fragment or derivative thereof is capable of binding to or interacting with low density lipoprotein receptor (LDLR); and (b) a cysteine rich region, wherein the cysteine rich region comprises a cysteine rich domain of LDLR, and wherein the cysteine rich region is capable of binding to or interacting with rhabdoviral G glycoprotein or a functional fragment or derivative thereof; wherein the cysteine rich region is covalently bonded to the rhabdoviral G glycoprotein or functional fragment or derivative thereof.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.